Prostate Cancer Medical Services in China

Prostate cancer is a malignant neoplasm originating in the prostate gland, predominantly affecting older men. It is among the most common non-cutaneous cancers globally, with incidence rising sharply after age 50. Risk factors include advancing age, family history, African ancestry, and certain genetic mutations (e.g., BRCA2). Clinical presentation varies—from asymptomatic detection via elevated serum prostate-specific antigen (PSA) and abnormal digital rectal examination to locally advanced disease causing urinary obstruction or metastatic symptoms such as bone pain. Diagnosis relies on multiparametric MRI, systematic and targeted transrectal ultrasound-guided biopsy, and genomic profiling where indicated. Staging integrates clinical assessment, imaging (e.g., PSMA-PET/CT), and pathological grading (Gleason score or Grade Group). Management is risk-stratified: active surveillance for low-risk disease; radical prostatectomy (open, laparoscopic, or robotic-assisted) or definitive radiotherapy (IMRT, SBRT, or brachytherapy) for intermediate- and high-risk localized cases; and multimodal systemic therapy—including androgen deprivation therapy (ADT), next-generation anti-androgens (e.g., enzalutamide), chemotherapy, and radioligand therapy (e.g., 177Lu-PSMA-617)—for recurrent or metastatic disease.

China offers compelling advantages for international patients seeking prostate cancer care. The country hosts nationally accredited oncology centers with internationally trained urologic oncologists and multidisciplinary tumor boards adhering to NCCN and EAU guidelines. Advanced technologies—including da Vinci Xi surgical systems, MR-guided focused ultrasound (MRgFUS), PSMA-PET/CT, and AI-enhanced radiation planning—are widely deployed in tier-1 hospitals. Five-year biochemical recurrence-free survival rates for localized disease exceed 90% in high-volume centers, supported by robust long-term follow-up data. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical standards—making comprehensive care, including genomic testing and novel therapeutics, significantly more accessible.

As a dedicated medical tourism agency, we facilitate seamless access to this high-quality care: coordinating appointments with top-tier hospitals, providing transparent, all-inclusive pricing packages, arranging visa support, medical translation, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.

China offers a compelling option for prostate cancer treatment, combining advanced oncology care with significant cost savings—typically 40–60% lower than equivalent care in the U.S. or Western Europe, without compromising clinical standards. Leading Chinese hospitals deploy state-of-the-art technologies including robotic-assisted laparoscopic surgery (da Vinci Xi systems), high-precision MRI-guided radiotherapy (e.g., MR-Linac), and next-generation genomic profiling for personalized therapy planning. Many oncology centers have treated over 1,000 prostate cancer cases annually, with multidisciplinary tumor boards led by urologic oncologists trained internationally. As a medical tourism agency, we provide transparent, itemized pricing upfront—no hidden fees—and assist patients in selecting JCI-accredited or NMPA-certified hospitals best matched to their clinical stage and preferences. Our team supports end-to-end coordination: pre-arrival consultations, visa documentation, accommodation, interpreter services, and post-treatment follow-up scheduling. Treatment timelines are streamlined, with diagnostic workups often completed within 3–5 business days and surgery scheduled within 1–2 weeks of arrival. All services adhere to international safety protocols and evidence-based guidelines endorsed by the Chinese Society of Clinical Oncology (CSCO) and EAU.

International Patient Treatment Process for Prostate Cancer (Oncology Department): The process begins with a remote consultation: patients submit medical records (including PSA levels, biopsy reports, MRI/CT scans, and prior treatment summaries) for oncologist review. Our agency schedules the initial appointment within 3–5 business days, coordinates visa support letters, and confirms travel dates. Upon arrival, we provide certified medical interpreters for all consultations, diagnostics, and consent discussions, plus in-person accompaniment to appointments and procedures. We arrange hotel accommodation near the hospital, assist with local transport, and facilitate pre-admission testing (e.g., bone scan, genomic profiling if indicated). Treatment—whether surgery (robotic-assisted laparoscopic prostatectomy), radiation therapy (IMRT or brachytherapy), or systemic therapy—is planned collaboratively by urologic oncologists, radiation oncologists, and medical oncologists. Post-treatment follow-up includes pathology review, PSA monitoring, and rehabilitation guidance. Required materials: ID/passport, complete diagnostic imaging and pathology slides (digitally or physically), treatment history, and insurance documentation. Total timeline: 2–4 weeks for evaluation and treatment initiation; full course duration varies by modality (e.g., 1–2 weeks for surgery + recovery; 6–8 weeks for radiation). All services include 24/7 English/Chinese/Arabic language support and dedicated international patient coordinators.

Medical Travel to China Guide: Prostate Cancer (Oncology)

Visa & Entry: Most patients apply for a 30- to 90-day L (tourist) or M (business) visa—our team provides official invitation letters from partner hospitals and assists with embassy coordination. A valid passport, completed application, and medical referral letter are required.

Medical Insurance & Payment: While Chinese hospitals do not accept foreign health insurance directly, we help verify coverage eligibility for reimbursement abroad and offer transparent, all-inclusive treatment packages—covering diagnostics, surgery (e.g., robotic prostatectomy), radiation therapy, and pathology—with no hidden fees. Payments can be made securely via wire transfer, credit card, or Alipay (with USD conversion). Our coordinators clarify costs upfront and support financial planning.

Accommodation & Companions: We arrange hospital-near apartments or partner hotels with kitchenettes, Wi-Fi, and accessibility features. One companion may stay free of charge in patient rooms (subject to hospital policy); additional guests receive discounted rates.

Follow-Up Care: Post-treatment, our clinical coordinators schedule virtual consultations with your oncologist, manage pathology report translations, share digital records via secure portal, and coordinate remote monitoring or local follow-up referrals—ensuring continuity of care after returning home.